The role of radiation therapy for de novo metastatic bladder and renal cancers - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Cancer/Radiothérapie Année : 2024

The role of radiation therapy for de novo metastatic bladder and renal cancers

Résumé

Metastatic bladder and renal cancers account respectively for 2.1% and 1.8% of cancer deaths worldwide. The advent of immune checkpoint inhibitors has revolutionized the management of metastatic disease, by demonstrating considerable improvements in overall survival. However, despite initial sensitivity to immune checkpoint inhibitors for most patients, both bladder and renal cancer are associated with short progression-free survival and overall survival, raising the need for further strategies to improve their efficacy. Combining systemic therapies with local approaches is a longstanding concept in urological oncology, in clinical settings including both oligometastatic and polymetastatic disease. Radiation therapy has been increasingly studied with either cytoreductive, consolidative, ablative or immune boosting purposes, but the long-term impact of this strategy remains unclear. This review intends to address the impact of radiation therapy with either curative or palliative intent, for synchronous de novo metastatic bladder and renal cancers.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée

Dates et versions

inserm-04517309 , version 1 (22-03-2024)

Identifiants

Citer

P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More